Tempus AI, Inc.

Case Overview
11 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 08/12/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Tempus AI, Inc. |
Court: | Court: Northern District of Illinois |
Case Number: | Case Number: 1:25cv06534 |
Class Period: | Class Period: 08/06/2024 - 05/27/2025 |
Ticker: | Ticker: TEM |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of Illinois on behalf of those who acquired Tempus AI, Inc. (“Tempus AI” or the “Company”) (NASDAQ:TEM) securities during the period of August 6, 2024 through May 27, 2025, inclusive (“the Class Period”). Investors have until August 12, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On May 28, 2025, Spruce Point Capital Management, LLC issued a research report on Tempus that raised numerous red flags over Tempus management, operations and financial reporting (the Spruce Point Report). The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) Tempus CEO Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus actual AI capabilities are over overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Companys recent financial guidance revision reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025.
The lawsuit alleges Tempus branded itself as an AI company despite having little history of generating significant revenues from AI solutions. Instead, the Company generated most of its revenues from acquisitions, genomic testing and data licensing agreements. Defendants repeatedly claimed that the contract value and quality of its data licensing agreements with life science companies were secure and expanding. The Company often reported on its relationship with long-term customer AstraZeneca as an example. Importantly, Tempus announced an expanding contract with AstraZeneca via a joint venture between the Company, AstraZeneca and Pathos AI. The Company similarly announced a joint venture with SoftBank as a way to generate revenue growth by entering the Japanese market. Tempus additionally claimed high revenue potential for Ambry Genetics, a target it acquired. The Company claimed Ambry Genetics accelerated growth was on account of its strong relationships with health care providers.
On May 28, 2025, Spruce Point Capital Management, LLC issued a research report on Tempus that raised numerous red flags over Tempus management, operations and financial reporting (the Spruce Point Report). The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) Tempus CEO Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus actual AI capabilities are over overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Companys recent financial guidance revision reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025.
The lawsuit alleges Tempus branded itself as an AI company despite having little history of generating significant revenues from AI solutions. Instead, the Company generated most of its revenues from acquisitions, genomic testing and data licensing agreements. Defendants repeatedly claimed that the contract value and quality of its data licensing agreements with life science companies were secure and expanding. The Company often reported on its relationship with long-term customer AstraZeneca as an example. Importantly, Tempus announced an expanding contract with AstraZeneca via a joint venture between the Company, AstraZeneca and Pathos AI. The Company similarly announced a joint venture with SoftBank as a way to generate revenue growth by entering the Japanese market. Tempus additionally claimed high revenue potential for Ambry Genetics, a target it acquired. The Company claimed Ambry Genetics accelerated growth was on account of its strong relationships with health care providers.